Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Supplemental material
  • Version history
  • Article usage
  • Citations to this article
Advertisement

ResearchIn-Press PreviewMetabolismNeuroscienceOncology Open Access | 10.1172/jci.insight.191465

Enhanced lipid metabolism serves as a metabolic vulnerability to polyunsaturated fatty acids in glioblastoma

Shiva Kant,1 Yi Zhao,1 Pravin Kesarwani,1 Kumari Alka,1 Jacob F. Oyeniyi,1 Ghulam Mohammad,1 Nadia Ashrafi,2 Stewart F. Graham,2 C. Ryan Miller,3 and Prakash Chinnaiyan1

1Department of Radiation Oncology, Corewell Health William Beaumont University Hospital, Royal Oak, United States of America

2Department of Metabolomics, Corewell Health Research Institute, Royal Oak, United States of America

3Department of Pathology, Division of Neuropathology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, United States of America

Find articles by Kant, S. in: PubMed | Google Scholar

1Department of Radiation Oncology, Corewell Health William Beaumont University Hospital, Royal Oak, United States of America

2Department of Metabolomics, Corewell Health Research Institute, Royal Oak, United States of America

3Department of Pathology, Division of Neuropathology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, United States of America

Find articles by Zhao, Y. in: PubMed | Google Scholar

1Department of Radiation Oncology, Corewell Health William Beaumont University Hospital, Royal Oak, United States of America

2Department of Metabolomics, Corewell Health Research Institute, Royal Oak, United States of America

3Department of Pathology, Division of Neuropathology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, United States of America

Find articles by Kesarwani, P. in: PubMed | Google Scholar

1Department of Radiation Oncology, Corewell Health William Beaumont University Hospital, Royal Oak, United States of America

2Department of Metabolomics, Corewell Health Research Institute, Royal Oak, United States of America

3Department of Pathology, Division of Neuropathology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, United States of America

Find articles by Alka, K. in: PubMed | Google Scholar

1Department of Radiation Oncology, Corewell Health William Beaumont University Hospital, Royal Oak, United States of America

2Department of Metabolomics, Corewell Health Research Institute, Royal Oak, United States of America

3Department of Pathology, Division of Neuropathology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, United States of America

Find articles by Oyeniyi, J. in: PubMed | Google Scholar

1Department of Radiation Oncology, Corewell Health William Beaumont University Hospital, Royal Oak, United States of America

2Department of Metabolomics, Corewell Health Research Institute, Royal Oak, United States of America

3Department of Pathology, Division of Neuropathology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, United States of America

Find articles by Mohammad, G. in: PubMed | Google Scholar

1Department of Radiation Oncology, Corewell Health William Beaumont University Hospital, Royal Oak, United States of America

2Department of Metabolomics, Corewell Health Research Institute, Royal Oak, United States of America

3Department of Pathology, Division of Neuropathology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, United States of America

Find articles by Ashrafi, N. in: PubMed | Google Scholar

1Department of Radiation Oncology, Corewell Health William Beaumont University Hospital, Royal Oak, United States of America

2Department of Metabolomics, Corewell Health Research Institute, Royal Oak, United States of America

3Department of Pathology, Division of Neuropathology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, United States of America

Find articles by Graham, S. in: PubMed | Google Scholar

1Department of Radiation Oncology, Corewell Health William Beaumont University Hospital, Royal Oak, United States of America

2Department of Metabolomics, Corewell Health Research Institute, Royal Oak, United States of America

3Department of Pathology, Division of Neuropathology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, United States of America

Find articles by Miller, C. in: PubMed | Google Scholar |

1Department of Radiation Oncology, Corewell Health William Beaumont University Hospital, Royal Oak, United States of America

2Department of Metabolomics, Corewell Health Research Institute, Royal Oak, United States of America

3Department of Pathology, Division of Neuropathology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, United States of America

Find articles by Chinnaiyan, P. in: PubMed | Google Scholar

Published December 9, 2025 - More info

JCI Insight. https://doi.org/10.1172/jci.insight.191465.
Copyright © 2025, Kant et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Published December 9, 2025 - Version history
View PDF
Abstract

Enhanced lipid metabolism, which involves the active import, storage, and utilization of fatty acids from the tumor microenvironment, plays a contributory role in malignant glioma transformation; thereby, serving as an important gain of function. In this work, through studies initially designed to understand and reconcile possible mechanisms underlying the anti-tumor activity of a high-fat ketogenic diet, we discovered that this phenotype of enhanced lipid metabolism observed in glioblastoma may also serve as a metabolic vulnerability to diet modification. Specifically, exogenous polyunsaturated fatty acids (PUFA) demonstrate the unique ability of short-circuiting lipid homeostasis in glioblastoma cells. This leads to lipolysis-mediated lipid droplet breakdown, an accumulation of intracellular free fatty acids, and lipid peroxidation-mediated cytotoxicity, which was potentiated when combined with radiation therapy. Leveraging this data, we formulated a PUFA-rich modified diet that does not require carbohydrate restriction, which would likely improve long-term adherence when compared to a ketogenic diet. The modified PUFA-rich diet demonstrated both anti-tumor activity and potent synergy when combined with radiation therapy in mouse glioblastoma models. Collectively, this work offers both a mechanistic understanding and a potentially translatable approach of targeting this metabolic phenotype in glioblastoma through diet modification and/or nutritional supplementation that may be readily integrated into clinical practice.

Graphical Abstract
graphical abstract
Supplemental material

View Supplementary Table 1

View Unedited blot and gel images

View

Version history
  • Version 1 (December 9, 2025): In-Press Preview

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Supplemental material
  • Version history
Advertisement
Advertisement

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts